SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Carbogen Amcis buys French CMO Creapharm Parenterals

By Gareth Macdonald , 17-Jan-2012
Last updated on 17-Jan-2012 at 14:39 GMT

Swiss API maker Carbogen Amcis has bought French contract manufacturer Creapharm Parenterals to boost capabilities in early-phase high potency drug development.

The deal – financial terms of which have not been disclosed – will see the French contract manufacturing organisation (CMO), formerly part of the Creapharm group, renamed as Carbogen Amcis SAS.

Through the acquisition Carbogen has gained Creapharm's facility in Riom, central France, which provides manufacturing services for injectable, liquid and semi-solid pharmaceutical forms. The 16 employees who work at the plant have also joined Carbogen.

A Carbogen spokesman told Outsourcing-pharma.com the move was designed to add capabilities in an area of manufacturing that is currently underserved by the contracting sector.

We felt that our customers would value the addition of early-phase drug product development services, particularly in highly potent drug products which are hard to come by.”

He added that: “We have been aware of the company for five or six years and saw it as a good opportunity to expand our service offering."

The deal comes almost a year after Carbogen – under the direction of Indian parent company Dishman – restructured operations to focus on the production of high potency active pharmaceutical ingredients (APIs) to address ‘inadequate profitability.’

But – while acquiring Creapharm Parenterals is ‘completely separate’ from Carbogen’s now completed realignment efforts – it does fit with the Swiss CMO’s overall market growth plan according to the spokesman.

Our strategic aim is to expand and diversify our offering to create a one-stop-shop for customers’ manufacturing needs and further secure the business.”

Dishman

In other news Carbogen’s parent company Dishman has signed up Charles Bowman & Co as its distributor for vitamin D3.

Under the deal vitamins made at Dishman’s plant in India – the construction of which is approaching completion - will be sold to pharmaceutical, animal feed and food manufacturers across North America.

The agreement – terms of which were not given – builds on the firms‘ existing relationship according to Rodney Fox, international sales and marketing director of Dishman Netherlands.

Charles Bowman and Company was a natural choice for us as they have worked with Dishman Netherlands for many years with our Vitamin D products and Cholesterol.”

Fox added that: “They bring not only an understanding of our operations but also considerable experience in the areas of marketing and distribution of vitamins and nutrition ingredients to the feed, food, and pharmaceutical markets.”

Subscribe to our FREE newsletter

Get FREE access to authoritative breaking news, videos, podcasts, webinars and white papers. SUBSCRIBE